Zetia Cost in Washington 2026: Prices, Insurance, Medicaid, and Compounded Options

Ezetimibe is the generic name for the cholesterol-lowering tablet sold under the brand name Zetia. It is an oral, once-daily, non-statin medication that reduces intestinal absorption of dietary and biliary cholesterol. It is not a statin, not a PCSK9 inhibitor, and not related to injectable GLP-1 medications. Ezetimibe is available both as a low-cost generic tablet and, less commonly, as a compounded preparation from a licensed compounding pharmacy.

The direct answer: for most Washington patients, what you pay for ezetimibe depends far more on which "price rail" you enter through than on the drug itself. Generic ezetimibe at a retail pharmacy with a discount coupon is typically a low-cost prescription, often cited in the range of $10 to $20 for a 30-day supply, while brand-name Zetia billed at list price can run into the hundreds of dollars per month. Washington Apple Health (Medicaid) covers ezetimibe but requires prior authorization, and a 503A compounding pharmacy may legally prepare it only when there is a documented clinical reason the commercial tablet will not work for that specific patient. Cash and coupon prices shift often and should always be checked at the pharmacy counter rather than assumed from any published figure, including this one.

Why this matters more than the sticker price suggests

Ezetimibe's cardiovascular benefit, established in the IMPROVE-IT trial (a large randomized cardiovascular outcomes trial in patients with recent acute coronary syndrome, published in the New England Journal of Medicine in 2015), builds over years of consistent use, not weeks. A medication that a patient cannot afford, or abandons because a pharmacy quoted a brand-tier price by mistake, delivers none of that benefit. The practical question for a Washington patient or prescriber is rarely "does ezetimibe work" but "which coverage or payment path gets this specific patient to consistent, affordable refills."

What ezetimibe actually costs in Washington

Generic ezetimibe 10 mg has been available since ezetimibe lost patent exclusivity, and multiple manufacturers now produce AB-rated generic versions, according to the FDA's Orange Book of approved drug products. Because retail cash prices, discount-card rates, and pharmacy chain pricing change frequently and vary by ZIP code and pharmacy, we are not publishing a single fixed dollar figure as authoritative. As a general orientation as of mid-2025, generic ezetimibe with a pharmacy discount coupon has commonly been reported in the low-double-digit range for a 30-tablet supply, while brand-name Zetia billed without insurance or a manufacturer coupon can run substantially higher, consistent with typical brand-versus-generic pricing gaps in this drug class. Confirm the actual price at the pharmacy counter, or through a current discount-card lookup, before you fill.

A note on the FDA approval: ezetimibe (brand Zetia) received FDA approval as a lipid-lowering agent in the early 2000s. Verify the exact approval date and indication language against the FDA's own application record before citing it precisely in clinical documentation. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Does Washington Apple Health (Medicaid) cover ezetimibe?

Yes, with prior authorization (PA). Washington's Medicaid pharmacy program operates under state administrative rules governing drug utilization review and prior authorization. Washington Administrative Code 182-530 sets the framework for how the Health Care Authority manages covered drugs, PA, and related pharmacy policy. Apple Health managed-care organizations administer PA under their own forms, but PA criteria for a non-statin lipid agent like ezetimibe generally require documentation that the patient has tried, or cannot tolerate, a statin at a clinically appropriate dose. Enrollees should confirm current PA turnaround requirements and appeal timelines directly with the Health Care Authority, since administrative rules and MCO-specific processes can change.

For general Apple Health enrollment and coverage information, consult Washington's Health Care Authority directly.

If a PA request is denied, Apple Health enrollees generally have an appeal or hearing pathway. Confirm the current appeal deadline directly with the Health Care Authority rather than relying on a fixed number, since administrative timelines are subject to change.

Does commercial insurance cover Zetia in Washington?

Commercial health plans sold or administered in Washington typically place generic ezetimibe on a lower cost-sharing tier than brand-name Zetia, consistent with standard formulary design across most US insurers. Exact tier placement, copay amounts, and whether prior authorization applies are plan-specific and change at least annually. There is no single answer that applies across Premera, Regence, Kaiser Permanente Washington, or an employer's self-funded plan. Self-funded ERISA plans are not bound by Washington state insurance mandates the way fully insured plans are.

What to actually do: call the number on the insurance card, ask specifically whether generic ezetimibe 10 mg is on the formulary, what tier it sits on, and whether prior authorization or step therapy applies. Ask the same question again at renewal, since formularies change yearly.

The Merck Zetia savings card

Merck has historically offered a brand-name savings card for Zetia that can lower out-of-pocket cost for commercially insured patients at participating pharmacies. These manufacturer copay programs consistently exclude patients enrolled in any government-funded insurance, including Medicaid (Apple Health), Medicare Part D, and TRICARE, because federal anti-kickback rules restrict manufacturer discounts for federal health program beneficiaries. If you are enrolled in Apple Health or Medicare, this card will not apply to you regardless of what a pharmacy display advertises. Confirm current eligibility terms and copay caps directly through Merck's patient program before assuming a specific dollar figure, since manufacturer program terms change without notice.

Is compounded ezetimibe legal in Washington?

Yes, but only under specific circumstances. Section 503A of the federal Food, Drug, and Cosmetic Act permits a licensed pharmacy to prepare a compounded medication for a particular patient when a valid prescription exists for that individual. Since ezetimibe is available as an FDA-approved commercial tablet in both brand and generic formulations, pharmacies may compound it only when a documented clinical necessity exists, such as a documented sensitivity to an inactive ingredient in the tablet formulation or a requirement for an alternative dose strength or delivery method. Compounding ezetimibe for reasons of cost savings or convenience alone, absent a genuine clinical need, does not align with the regulatory framework established by Section 503A.

FDA, human drug compounding and outsourcing facilities

Washington's Pharmacy Quality Assurance Commission licenses and inspects compounding pharmacies operating in the state. Patients considering a compounded ezetimibe product should verify the pharmacy's active license status directly with the state board rather than taking a clinic's word for it.

Washington's Pharmacy Quality Assurance Commission maintains licensing records that can be checked directly with the state board.

Compounded ezetimibe is not FDA-approved and has not undergone the bioequivalence testing that generic tablets require. It is not automatically interchangeable with the commercial product. Any claim that a specific Washington clinic provides compounded ezetimibe "at no drug cost" describes a business or membership model, not a regulatory entitlement, and should be verified with that clinic directly rather than assumed to apply broadly.

Can you get ezetimibe through telehealth in Washington?

Ezetimibe is not a controlled substance, and it does not carry the additional telehealth prescribing restrictions that apply to controlled medications under federal law. A Washington-licensed prescriber can generally evaluate a patient and prescribe ezetimibe through a telehealth visit, sending the prescription electronically to a pharmacy of the patient's choice. Washington has telehealth coverage and payment parity provisions in state law; the exact statutory citation and its current scope should be verified against the current Revised Code of Washington rather than assumed unchanged, since telehealth statutes have been amended multiple times in recent years.

What the trial evidence actually supports

The IMPROVE-IT trial randomized patients recently hospitalized for acute coronary syndrome to a statin alone or a statin plus ezetimibe, and found a statistically significant, modest reduction in a composite cardiovascular endpoint (cardiovascular death, major coronary events, and stroke) in the combination arm over several years of follow-up. This is trial-level evidence, not an observational association, and it is the primary basis cited by US cardiology guidelines for adding ezetimibe when LDL-C remains above target on a maximally tolerated statin. We are intentionally not restating the exact percentage-point event rates or absolute risk reduction from that trial here, because the specific figures should be verified against the original 2015 New England Journal of Medicine publication before being used in clinical or patient-facing materials; treat any precise number attached to IMPROVE-IT that you encounter online, including in earlier versions of pages like this one, as something to confirm rather than quote from memory.

What is established: ezetimibe lowers LDL cholesterol both as monotherapy and added to a statin, and adding it to statin therapy after acute coronary syndrome produced a measurable, statistically significant reduction in cardiovascular events in a large randomized trial.

What is plausible but not separately proven for every patient population: that the same magnitude of benefit applies uniformly to patients without prior cardiovascular events, or to patients using it purely for primary prevention with only mild LDL elevation. Guideline bodies generally reserve the strongest recommendation for secondary prevention or high-risk primary prevention patients not at goal on a statin.

What is not established from the material available here: any specific comparison of ezetimibe's cost-effectiveness against PCSK9 inhibitors in Washington's Medicaid population, and any Washington-specific adherence or outcomes data tied to insurance type. Broad national adherence figures should not be presented as if they describe Washington Apple Health enrollees specifically unless a Washington-specific source is cited.

Safety, interactions, and who should not take it without discussion

Ezetimibe demonstrates favorable tolerability when used alone. In dual therapy with a statin, patients are subject to the myopathy risk inherent to the statin component; ezetimibe as a single agent has not shown a demonstrable increase in muscle-related adverse events based on published clinical trial data, although current prescribing information should be consulted for the most recent incidence rates rather than relying on older reference summaries.

Two interactions are worth flagging for any prescriber or pharmacist:

• Cyclosporine meaningfully increases ezetimibe blood levels; concurrent use requires clinical judgment and monitoring.
• Bile acid sequestrants (such as cholestyramine) reduce ezetimibe absorption; ezetimibe should generally be dosed several hours apart from a sequestrant, per FDA labeling.

Zetia (ezetimibe) FDA application record

Ezetimibe, like other lipid-lowering therapies, is generally not recommended during pregnancy because lipid management is rarely urgent enough to justify use in the absence of pregnancy-specific safety data. Anyone who is pregnant or planning pregnancy should discuss lipid management options directly with their prescriber rather than continuing or starting ezetimibe on the assumption that it is safe.

This is general education, not individualized dosing or treatment advice. A patient with muscle pain, dark urine, jaundice, or signs of an allergic reaction after starting ezetimibe should contact their prescriber promptly, and anyone with chest pain, shortness of breath, or stroke-like symptoms should seek emergency care immediately regardless of what medication they are taking.

A practical path to the lowest reasonable price

1. Ask for generic ezetimibe by name, not "Zetia." Nearly every Washington pharmacy stocks a generic version.
2. Check a discount-card price before assuming your insurance copay is lower. For uninsured or high-deductible patients, a coupon price is sometimes lower than a commercial copay.
3. If income-eligible, apply for Apple Health. Confirm current income thresholds directly with the Washington Health Care Authority, since federal poverty level figures are updated annually.
4. If your prescriber recommends compounded ezetimibe, ask why the commercial tablet will not work for you. A clear clinical answer (documented allergy, swallowing difficulty) is a legitimate 503A justification; "it's cheaper" or "it's more natural" is not.
5. Ask about a 90-day supply once your dose is stable. Longer fill intervals reduce the number of times cost becomes a barrier to refilling.

Verification checklist: what is stable versus what you must re-check

Some facts about ezetimibe are federally and clinically stable and unlikely to change quickly. Others are state, insurer, or pharmacy-specific and can change month to month. Confusing the two is the most common way this kind of cost article goes stale. Use this checklist before relying on any claim in this article or elsewhere.

Stable facts (federal/clinical, low volatility):

• Ezetimibe is FDA-approved as a lipid-lowering, non-statin oral tablet; mechanism is inhibition of intestinal cholesterol absorption via NPC1L1.
• Ezetimibe is not a controlled substance.
• 503A compounding of a commercially available drug like ezetimibe requires a documented, patient-specific clinical justification under federal law.
• The IMPROVE-IT trial is the primary randomized-trial basis for ezetimibe's cardiovascular outcome benefit when added to a statin.
• Cyclosporine and bile acid sequestrants have clinically relevant pharmacokinetic interactions with ezetimibe.

Date-sensitive facts (re-verify before quoting or acting on them):

• Cash and discount-card price for generic ezetimibe at any specific Washington pharmacy.
• Brand Zetia list price and whether a manufacturer savings card is currently active, and its exact copay cap and exclusions.
• Which Washington commercial insurer places generic ezetimibe on which formulary tier, and whether prior authorization applies.
• Apple Health prior-authorization criteria, appeal deadlines, and income eligibility thresholds for the current plan year.
• Whether a specific Washington clinic's compounded-ezetimibe or membership model is currently operating, and whether the dispensing pharmacy holds an active 503A license.
• The exact current text and scope of Washington's telehealth prescribing and payment-parity statutes.

If a number in any article, including this one, is not dated to a specific month and year, treat it as an estimate rather than a quote-ready fact.